Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: A monocentric study over three decades

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 471-478

  Michonneau, David ^a,b   Suarez, Felipe ^a,b   Lambert, Jérôme ^b,c,d   Adam, Julien ^a,b   Brousse, Nicole ^a,b   Canioni, Danielle ^a,b   Anglicheau, Dany ^a,b   Martinez, Frank ^a,b   Snanoudj, Renaud ^a,b   Legendre, Christophe ^a,b   Hermine, Olivier ^a,b   Mamzer Bruneel, Marie France ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSERM   (France)

Author keywords

chemotherapy; kidney transplantation; post transplantation lymphoproliferative disorders; prognosis; rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; CALCINEURIN INHIBITOR; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; PREDNISOLONE; PREDNISONE; PURINE ANTAGONIST; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG MEGADOSE; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; LONG TERM CARE; LONGITUDINAL STUDY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; SURVIVAL TIME; T CELL LYMPHOMA; VIRUS LOAD; VIRUS REACTIVATION;

EID: 84874537535     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs476     Document Type: Article

References (51)

1. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849
2. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, 2008
3. Quinlan SC, Pfeiffer RM, Morton LM et al. Risk factors for earlyonset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206-209
4. Bakker NA, van Imhoff GW, Verschuuren EAM et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19: 327-334 (Pubitemid 40711965)
5. Birkeland SA, Hamilton-Dutoit S, Sandvej K et al. EBV-induced post-transplant lymphoproliferative disorder (PTLD). Transplant Proc 1995; 27: 3467-3472 (Pubitemid 26016276)
6. Khedmat H, Alavian S, Taheri S. Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant 2010; 15: 40-44
7. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transplant Infect Dis 2001; 3: 60-69 (Pubitemid 32452920)
8. Rees L, Thomas A, Amlot PL. Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppression. Lancet 1998; 352: 789 (Pubitemid 28404569)
9. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587 (Pubitemid 14156511)
10. Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088 (Pubitemid 32448822)
11. Timms JM, Bell A, Flavell JR et al. Target cells of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003; 361: 217-223 (Pubitemid 36126222)
12. Ghobrial IM, Habermann TM, Maurer MJ et al. Prognostic analysis for survival in adult solid organ transplant recipients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2005; 23: 7574-7582 (Pubitemid 46291821)
13. Swinnen LJ, Mullen GM, Carr TJ et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333-3340
14. Dotti G, Fiocchi R, Motta T et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002; 74: 1095-1102 (Pubitemid 35216102)
15. Leblond V, Davi F, Charlotte F et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052-2059 (Pubitemid 28265040)
16. Nelson BP, Nalesnik MA, Bahler DW et al. Epstein-Barr virusnegative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375-385 (Pubitemid 30127473)
17. Swinnen LJ, LeBlanc M, Grogan TM et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008; 86: 215-222
18. Lee J-J, Lam MSH, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacotherapy 2007; 41: 1648-1659 (Pubitemid 47485625)
19. Blaes AH, Peterson BA, Bartlett N et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104: 1661-1667 (Pubitemid 41437429)
20. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057
21. González-Barca E, Domingo-Domenech E, Capote FJ et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007; 92: 1489-1494 (Pubitemid 350144124)
22. Oertel SHK, Verschuuren E, Reinke P et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906 (Pubitemid 43923950)
23. Trappe R, Oertel S, Leblond V et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell posttransplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13: 196-206
24. Mamzer-Bruneel MF, Lomé C, Morelon E et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622-3632
25. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586 (Pubitemid 350002966)
26. Caillard S, Lamy FX, Quelen C et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French Registry and analysis of subgroups of lymphomas. Am J Transplant 12: 682-693
27. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932 (Pubitemid 28446681)
28. Faye A, Van Den Abeele T, Peuchmaur M et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998; 352: 1285 (Pubitemid 28470350)
29. Maloney DG, Grillo-López AJ, Bodkin DJ et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274 (Pubitemid 27419340)
30. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195 (Pubitemid 27392702)
31. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11(Suppl 1): 113-116
32. Verschuuren EAM, Stevens SJC, van Imhoff GWet al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73: 100-104 (Pubitemid 34094694)
33. Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001; 20: 770-772 (Pubitemid 32633879)
34. Choquet S, Oertel S, LeBlond V et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86: 599-607 (Pubitemid 47018478)
35. Trappe R, Riess H, Babel N et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007; 83: 912-918 (Pubitemid 46682732)
36. Buell JF, Gross TG, Hanaway MJ et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 956-957 (Pubitemid 40590757)
37. Choquet S, Trappe R, Leblond V et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274 (Pubitemid 46852438)
38. Oertel SH, Papp-Váry M, Anagnostopoulos I et al. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 2003; 123: 830-835 (Pubitemid 37533294)
39. Elstrom RL, Andreadis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576. (Pubitemid 43382145)
40. Orjuela M, Gross TG, Cheung Y-K et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9: 3945S-52S-S-52S
41. Evens AM, David KA, Helenowski I et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 28: 1038-1046
42. Caillard S, Lelong C, Pessione F et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735-2742 (Pubitemid 44571695)
43. Leblond V, Dhedin N, Mamzer Bruneel MF et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772-778 (Pubitemid 32119092)
44. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Eng J Med 1993; 329: 987-994
45. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861 (Pubitemid 46348180)
46. Muti G, Cantoni S, Oreste P et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 67-77 (Pubitemid 34101115)
47. Parker A, Bowles K, Bradley JA et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS guidelines. Br J Haematol 2010; 149: 693-705
48. Peyrade F, Gastaud L, Re D et al. Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol 2012; 13: e344-e352
49. Trappe R, Hinrichs C, Appel U et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009; 9: 2331-2337
50. Johnson SR, Cherikh WS, Kauffman HM et al. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 2006; 6: 2743-2749 (Pubitemid 44571696)
51. Karras A, Thervet E, Le Meur Y et al. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant 2004; 4: 1904-1909. (Pubitemid 39434453)